Pharmaceuticals
27.03.2019
Refining relabeling of pharmaceuticals
Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.03.12.2018
Swiss Life Sciences – ready for R&D 2030?
Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.19.11.2018
Swap, don’t sell: Driving value through asset swaps
The Swiss Pharmaceuticals sector produced four USD1 billion+ deals in the first half of 2018. This is not surprising given the efforts by Pharmaceuticals and Life Sciences businesses to push new boundaries and continuously innovate.05.06.2018
Expanding right into Europe
Innovation is the life source of Life Sciences. But strategic and meticulous planning is key to commercial success, especially when entering a new regional market.14.03.2018
Das neue Heilmittelgesetz: Fluch oder Segen?
Das neue Heilmittelgesetz wurde zwar bereits vor 2 Jahren verabschiedet, in Kraft tritt es jedoch vermutlich erst am 1. Januar 2019, nach Abschluss des umfangreichen Vernehmlassungsverfahrens. Ziel und Zweck des Gesetzes ist die Regelung der Zulassung und des Vertriebs von Arzneien.10.03.2017